Vaccination of Patients With Inflammatory Bowel Disease: Reported Practice
| Vaccination Task | Gastroenterologists n=50 | Primary Care Providers n=87 | Difference (95% confidence interval) | P Value |
|---|---|---|---|---|
| Check varicella immunoglobulin G and vaccinate accordingly | 7 (14) | 6 (7) | 7 (−3 to 20) | 0.9 |
| Check varicella immunoglobulin G >4 weeks prior to starting biologics and vaccinate accordingly | 7 (14) | 7 (8) | 6 (−4 to 19) | 0.3 |
| Select inactivated influenza vaccine if on immune-suppressive therapy | 33 (66) | 73 (84) | 18 (3 to 33) | 0.02 |
| Select inactivated influenza vaccine for households if patient on immune-suppressive therapy | 11 (22) | 14 (16) | 6 (−7 to 21) | 0.4 |
| Warn immune-compromised patients against handling diapers of rotavirus-vaccinated infants for 4 weeks | 5 (10) | 5 (6) | 4 (−5 to 16) | 0.4 |
| Warn immune-compromised patients against contact with varicella/zoster-vaccinated persons with skin lesions | 18 (36) | 24 (28) | 8 (−8 to 24) | 0.3 |
| Provide zoster vaccine if age ≥50 years | 14 (28) | 34 (39) | 11 (−6 to 26) | 0.2 |
| Provide zoster vaccine >4 weeks before starting biologics if age ≥50 years | 13 (26) | 19 (22) | 4 (−10 to 19) | 0.6 |
| Provide annual influenza vaccine | 43 (86) | 79 (91) | 5 (6 to 18) | 0.4 |
| Provide age-appropriate vaccinations prior to immune-suppressive therapy | 35 (70) | 44 (51%) | 19 (2 to 34) | 0.03 |
| Provide appropriate pneumonia vaccine if on immune-suppressive therapya | 18 (36) | 54 (62) | 26 (9 to 41) | 0.004 |
| Assess vaccination status in general | 35 (70) | 53 (61) | 9 (−8 to 24) | 0.3 |
| Assess for hepatitis-A vaccine | 30 (60) | 34 (39) | 21 (4 to 37) | 0.02 |
| Assess for hepatitis-B vaccine | 43 (86) | 49 (56) | 30 (14 to 43) | 0.0003 |
| Assess for pertussis vaccine | 7 (14) | 38 (44) | 30 (14 to 43) | 0.0003 |
| Assess for diphtheria vaccine | 10 (20) | 42 (48) | 28 (11 to 42) | 0.001 |
| Assess for meningococcal vaccine | 13 (26) | 24 (28) | 2 (−14 to 16) | 0.8 |
| Assess for human papilloma vaccine | 14 (28) | 18 (21) | 7 (−7 to 22) | 0.4 |
| Assess for measles vaccine | 11 (22) | 25 (29) | 7 (−9 to 21) | 0.4 |
| Assess for mumps vaccine | 11 (22) | 25 (29) | 7 (−9 to 21) | 0.4 |
| Assess for rubella vaccine | 11 (22) | 25 (29) | 7 (−9 to 21) | 0.4 |
↵aProvide pneumonia vaccination with PCV13 (Prevnar), followed by PPSV23 (Pneumovax) ≥8 weeks later, followed by PPSV23 booster after 5 years.
Notes: Data are reported as number (%) of respondents who answered “always” or “most of the time” or who routinely assessed for the listed vaccines. The Difference column reports the difference in percentage points. P values are 2-sided.